Latin America and the Caribbean vs Sri Lanka: Percentage of bloodstream infection due to Escherichia coli resistant
Latin America and the Caribbean
30.9%
in 2022
Sri Lanka
58.8%
in 2022
Latin America and the Caribbean rank
13th
Sri Lanka rank
12th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Latin America and the Caribbean
- Sri Lanka
How they compare
Sri Lanka currently reports 58.8% against 30.9% in Latin America and the Caribbean, a difference of 27.9%.
That makes Sri Lanka's figure about 1.9 times Latin America and the Caribbean's.
Across all 5 years both countries report, Sri Lanka has been ahead every year.
Latin America and the Caribbean ranks 13th and Sri Lanka ranks 12th of 16 groups.
Sri Lanka has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Latin America and the Caribbean | Sri Lanka | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 20.2% | 65.3% | 45.1% | Sri Lanka |
| 2020s | 28.3% | 59.2% | 30.9% | Sri Lanka |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Latin America and the Caribbean or Sri Lanka?
- Sri Lanka, at 58.8% against 30.9% in Latin America and the Caribbean as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Latin America and the Caribbean and Sri Lanka?
- 27.9%, with Sri Lanka ahead.
- How many years of comparable data are there for Latin America and the Caribbean and Sri Lanka?
- 5 years are reported by both, from 2018 to 2022.
- How do Latin America and the Caribbean and Sri Lanka rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Latin America and the Caribbean ranks 13th and Sri Lanka ranks 12th of 16 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.